Suze Orman Told You to Buy SpaceX at $200, So Who Is Telling You to Sell at $136?

Photo of Jake Fitzgerald
By Jake Fitzgerald Published

Quick Read

  • Suze Orman's June 2026 advice to dollar-cost average into SPCX near $200 left followers underwater as the stock dropped to $136 and drew a fresh Sell initiation.

  • SpaceX posted a $541 million quarterly loss against $18.37 billion in capex, while a lockup expiration released 911 million new shares into the market.

  • Orman never specified a position-size cap, meaning a listener with 25% of a $500,000 portfolio in SPCX lost over $33,000 following identical advice.

  • Many financial professionals are salespeople paid on what they push, not whether you end up wealthier. A fiduciary is the opposite. The SEC legally requires them to put your interests first. Advisor.com's free matching tool pairs you with vetted fiduciaries from major national firms, all in under three minutes. See who you match with today.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Suze Orman Told You to Buy SpaceX at $200, So Who Is Telling You to Sell at $136?

© Leigh Vogel / Stringer / Getty Images North America

On her June 18, 2026 podcast, Suze Orman told listeners that if they wanted exposure to Elon Musk’s newly public rocket company, the cleanest way was to dollar cost average into the stock itself, symbol SPCX, at around $200. That day, SpaceX (NASDAQ:SPCX | SPCX Price Prediction) closed at $185. This morning it changed hands near $136, and an analyst desk flagged a fresh Sell initiation on the name, one of several bearish calls now on the Street.

If you followed Orman’s advice and put $500 a month into SPCX starting June 18, you are underwater on nearly every tranche. Orman’s core audience is retirees and near-retirees who trust her voice on capital preservation. A single-stock DCA into a pre-profit, capex-heavy IPO is a different animal than what most of that audience signed up for.

SPCX price target

Why This Advice Was Structurally Wrong for the Audience

Dollar cost averaging reduces timing risk in a diversified portfolio. It is a poor tool for reducing valuation risk in a single stock. Orman conflated these different problems.

If you committed $500 a month for the three months since that podcast, and SPCX went from $185 on June 18 to about $136 today, your average cost sits somewhere in the mid-$150s. That is a 28% drawdown on your first buy and a smaller loss on later ones. DCA cushioned the pain but did not eliminate it. The deeper question is whether the business supports the price at any of those levels.

The Q2 report provides the raw material. SpaceX beat on revenue at $7.81 billion versus $6.93 billion expected, with Starlink and AI leading the mix. The $541 million net loss and the $18.37 billion of capital spending in a single quarter, $15.83 billion of it on AI compute, tell the other side of the story. A company burning that much cash to build data centers is a venture bet with a ticker, categorically different from a bond substitute (we profiled seven suppliers riding that same buildout, from power to cooling, in a free AI infrastructure report).

Reddit noticed what Orman did not price in. On August 7, roughly 911.5 million shares held by employees and early investors became eligible to trade. As one poster put it, “That’s more than the roughly 639M shares sold in the IPO”. Buying near the highs before that supply event is the opposite of what dollar cost averaging protects against.

Position Size Changes Everything

The single factor determining whether Orman’s advice was reckless or merely aggressive is what percentage of your portfolio you put into it.

Consider two listeners. Listener A hears “dollar cost average” and puts 2% of a $500,000 portfolio into SPCX at $185. The stock falls to $136. The loss is roughly $2,650, or half a percent of the total account. Annoying, not life-changing. Listener B puts 25% of the same portfolio in. Same drawdown, but now the account is down more than $33,000, and the retirement math bends.

Both followed the exact same advice. One is fine. One is not. Orman’s on-air instruction did not specify a cap, and that omission is where the harm lives.

What to Do Now if You Bought the Podcast

  1. Total your SPCX cost basis and divide it by your investable assets. If the number is above 5%, the position is a concentrated bet, not a DCA sleeve. Decide if you meant to make a concentrated bet.
  2. Read the Q2 filing yourself. Revenue growth is real, but so is a $541 million quarterly loss against $18.37 billion in capex. Decide whether you are comfortable owning that profile.
  3. Track the analyst view. Today’s Sell initiation is one of several bearish ratings. Note the price target when published and compare to your average cost.
  4. Set a rule before the next unlock. The 911.5 million share event is behind you. More lockup expirations are ahead. Decide in advance what price or fundamental change would cause you to trim.

At least one member of Congress, Rep. Timmons, disclosed a SpaceX purchase on July 18, 2026, and this morning Musk himself was busy retweeting a post calling X “the nervous system of the world” rather than addressing the stock. Both are noise around the ticker, a reminder that the loudest voices on a stock rarely have your retirement in mind.

SPCX analyst ratings

Dollar cost averaging manages timing risk, not the risk that you picked the wrong stock at the wrong price.

Contact [email protected] for any questions or corrections.

Photo of Jake Fitzgerald
About the Author Jake Fitzgerald →

Continue Reading

Top Gaining Stocks

MRNA Vol: 51,659,638
COIN Vol: 12,878,281
ALB Vol: 1,263,939
FCX Vol: 17,240,618
MOS Vol: 3,813,671

Top Losing Stocks

CTRA Vol: 73,319,495
SRE Vol: 1,280,467
EQR Vol: 17,443,069
EIX Vol: 735,174
PWR Vol: 444,024